Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a webcast with key opinion leaders on May 2, 2021, at 7:00 AM PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a webcast with key opinion leaders on May 2, 2021, at 7:00 AM PT. The event will feature data from the OPTIC clinical trial for ADVM-022, a gene therapy for wet age-related macular degeneration, and preclinical findings on ADVM-062 for blue cone monochromacy. Presentations will occur on May 3, 2021, during the ARVO 2021 Virtual Meeting. Additionally, on May 6, 2021, Adverum will report first-quarter 2021 financial results. More details can be found on Adverum's website.
Details
News Market Reaction – ADVM
The recorded move for ADVM in the trading session of this news was -5.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT --
REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of additional clinical data for Cohorts 1-4 in the OPTIC clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in wet age-related macular degeneration (wet AMD) during the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Meeting. Preclinical data on ADVM-062, a novel IVT gene therapy that also utilizes Adverum’s proprietary vector capsid AAV.7m8, in blue cone monochromacy will also be presented.
Presentation Title: Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)
Session: AMD: Clinical research - New Therapies and Technologies
Date and Time: May 3, 2021 from 4:30 PM to 6:00 PM ET
Presenter: Brandon G. Busbee, M.D., partner, Tennessee Retina Physicians
Poster Title: Preclinical Evaluation of ADVM-062, a Novel Intravitreal Gene Therapy for the Treatment of Blue Cone Monochromacy
Session: Drug Delivery and Gene Therapy
Date and Time: May 3, 2021 from 11:15 AM to 1:00 PM ET
Presenter: Ruslan Grishanin, director translational science, Adverum Biotechnologies
On Saturday, May 1, 2021 at 7:00 AM ET, the virtual presentations will be available on demand to ARVO participants. Adverum plans to post the ADVM-022 OPTIC presentation under Events and Presentations in the Investors section of Adverum’s website. The ADVM-062 BCM poster will be available in the Publications section of Adverum’s website.
Adverum Webcast
Date: May 2, 2021
Time: 7:00 – 8:30 AM PT (10:00 – 11:30 AM ET)
Key Opinion Leaders Participating:
- Brandon G. Busbee, M.D., partner, Tennessee Retina Physicians; Investigator in OPTIC
- Jeffrey S. Heier, M.D., director of the Vitreoretinal Service and director of Retina Research at Ophthalmic Consultants of Boston
The live video webcast will be accessible under Events and Presentations in the Investors section of Adverum's website. To participate in the conference call, dial 1-877-705-6003 (domestic) or 1-201-493-6725 (international) and refer to the “Adverum Biotechnologies’ OPTIC Clinical Data Discussion Conference Call.” It is recommended call participants dial in 15 minutes in advance. The archived audio webcast will be available on Adverum’s website following the call and will be available for 30 days.
On May 6, 2021 after market, Adverum plans to report recent business progress and financial results for the first quarter of 2021.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.